Tag Nivolumab

Clinical Trials, News

CheckMate-9DW trial evaluating Opdivo plus Yervoy meets primary endpoint of overall survival

Bristol Myers Squibb today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS)…

March 20, 2024

New Treatments, News

FDA approved Opdivo® for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma.

Bristol Myers Squibb today announced that Opdivo®(nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon…

October 13, 2023